
-$P(O)NR^aR^b$, -$P(O)_2NR^aR^b$, -$P(O)OR^a$, -$P(O)_2OR^a$, -CN, or -NO_2; or R^8 and R^9 or R^9 and R^{10} taken together with the carbons to which they are attached form a C_4-C_6 cycloalkyl, a 4- to 7-membered heterocycloalkyl, or a C_6-C_{10} aryl, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_4-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, or 4- to 7-membered heterocycloalkyl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OR^e, -$OC(O)R^e$, -$OC(O)NR^eR^f$, -$OS(O)R^e$, -$OS(O)_2R^e$, -$OS(O)NR^eR^f$, -$OS(O)_2NR^eR^f$, -SR^e, -$S(O)R^e$, -$S(O)_2R^e$, -$S(O)NR^eR^f$, -$S(O)_2NR^eR^f$, -NR^eR^f, -$NR^eC(O)R^f$, -$NR^eC(O)OR^f$, -$NR^eC(O)NR^eR^f$, -$NR^eS(O)R^f$, -$NR^eS(O)_2R^f$, -$NR^eS(O)NR^eR^f$, -$NR^eS(O)_2NR^eR^f$, -$C(O)R^e$, -$C(O)OR^e$, -$C(O)NR^eR^f$, -PR^eR^f, -$P(O)R^eR^f$, -$P(O)_2R^eR^f$, -$P(O)NR^eR^f$, -$P(O)_2NR^eR^f$, -$P(O)OR^e$, -$P(O)_2OR^e$, -CN, or -NO_2;

[031] each R^a, R^b, R^c, R^d, R^e, and R^f is independently selected from the group consisting of H, deuterium, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, C_1-C_6 alkyl-C_6-C_{10} aryl, and 5- to 10-membered heteroaryl;

[032] m is 0, 1, 2, 3, or 4; and

[033] n is 2, 3, 4, 5, 6, 7, or 8.


[034] In some ~~embodiment~~examples, the disclosure provides a compound of the formula II, or a pharmaceutically acceptable salt thereof,



II

[035] wherein R^1, R^2, A, L, X, X^1, X^2, X^3, X^4, Y, Y^1, Y^2, Z, m and n are as described herein.


[036] In some ~~embodiment~~examples, the disclosure provides a compound of the formula III, or a pharmaceutically acceptable salt thereof,



III

[037] wherein R^1, A, L, X, X^1, X^2, X^3, X^4, Y, Y^2, Z, Z^1, m and n are as described herein.


[038] In some ~~embodiment~~examples, the disclosure provides a compound of the formula IV, or a pharmaceutically acceptable salt thereof,



IV

[039] wherein R^1, R^2, A, L, X, X^1, X^2, X^3, X^4, Y, Y^1, Y^2, Z, m and n are as described herein.


[040] In some ~~embodiment~~examples, the disclosure provides a compound of the formula V, or a pharmaceutically acceptable salt thereof,



V

[041] wherein R^1, A, L, X, X^1, X^2, X^3, X^4, Y, Y^1, Z, Z^1, m and n are as described herein.


[042] In some ~~embodiment~~examples, the disclosure provides a compound of the formula VI, or a pharmaceutically acceptable salt thereof,



VI

[043] wherein R^1, R^2, A, L, X, X^1, X^2, X^3, X^4, Y, Y^1, Y^2, Z, m and n are as described herein.


[044] In some ~~embodiment~~examples, the disclosure provides a compound of the formula VII, or a pharmaceutically acceptable salt thereof,



VII










wherein R^1, R^2, A, B, L, X, X^1, X^2, X^3, X^4, Y, Y^1, Y^2, Z, m and n are as described herein.

[045] In some ~~embodiment~~examples, the disclosure provides a compound of the formula VIII, or a pharmaceutically acceptable salt thereof,







































VIII

[046] wherein R^1, R^2, A, B, L, X, X^1, X^2, X^3, X^4, Y, Y^1, Y^2, Z, m and n are as described herein.

[047] In some ~~aspects examples of each of the above embodiments~~, Ring B (Z) is not , , , , , , or . In some ~~embodiment~~examples, Ring B (Z) is not , or .

[048] In some ~~aspect~~examples~~ of the embodiments herein~~, C(R^9) is H. In some ~~aspect~~examples~~ of the embodiments herein~~, C(R^9) is not –Cl. In some ~~embodiments~~examples, C(R^{10}) is H. In some ~~aspect~~examples~~ of the embodiments herein~~, C(R^{10}) is not –Cl.

[049] In some ~~aspect~~examples~~ of the embodiments herein~~, the compound is not a compound wherein Ring B (Z) is , , , , , , , and R^9 and/or R^{10} is not H. In some ~~embodiments~~examples, the compound is not a compound wherein Ring B (Z) is  or , and R^9 and/or R^{10} is not H. In some ~~aspect~~examples~~ of the embodiments herein~~, the compound is not a compound wherein X^1 is C(R^7), X^3 is C(R^9), X^4 is C(R^{10}), R^9 and/or R^{10} is not H, and Ring B (Z) is , , , , , , , or . In some ~~aspect~~examples~~ of the embodiments herein~~, the compound is not a compound wherein X^1 is C(R^7), X^3 is C(R^9), X^4 is C(R^{10}), R^9 and/or R^{10} is not H, and Ring B (Z) is  or . In some ~~aspect~~examples~~ of the embodiments herein~~, the compound is not a compound wherein X^1 is C(R^7), X^3 is C(R^9), X^4 is C(R^{10}), R^9 and/or R^{10} is –Cl, and Ring B (Z) is , , , , , , , or . In some ~~aspect~~examples~~ of the embodiments herein~~, the compound is not a compound wherein X^1 is C(R^7), X^3 is C(R^9), X^4 is C(R^{10}), R^9 and/or R^{10} is–Cl, and Ring B (Z)

is , or . In some ~~aspect~~examples~~ of the embodiments herein~~, X^1 is $C(R^7)$, X^3 is $C(R^9)$, X^4 is $C(R^{10})$, and R^9 and/or R^{10} is not –Cl. In some ~~embodiments~~examples, X^1 is $C(R^7)$, X^3 is $C(R^9)$, X^4 is $C(R^{10})$, R^9 and/or R^{10} is not –Cl, and Ring B (Z) is not , , , , , , or . In some ~~aspect~~examples~~ of the embodiments herein~~, X^1 is $C(R^7)$, X^3 is $C(R^9)$, X^4 is $C(R^{10})$, R^9 and/or R^{10} is not –Cl, and Ring B (Z) is not  or .

[050] In certain ~~embodiments of the above aspect~~examples, the compound of Formula (I)-(VIII) is a compound selected from those species described or exemplified in the detailed description below.

[051] In further ~~aspects~~examples, the disclosure relates to a pharmaceutical composition comprising at least one compound of Formula (I)-(VIII) or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions according to the disclosure may further comprise a pharmaceutically acceptable excipient.

[051a] In another aspect, there is provided a pharmaceutical composition comprising at least one compound as defined above, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable excipients.

[052] In further ~~aspect~~examples, the disclosure relates to a compound of Formula (I)-(VIII), or a pharmaceutically acceptable salt thereof, for use as a medicament.

[053] In further ~~aspect~~examples, the disclosure relates to a method of treating disease, such as cancer comprising administering to a subject in need of such treatment an effective amount of at least one compound of Formula (I)-(VIII), or a pharmaceutically acceptable salt thereof.

[053a] In another aspect, there is provided the use of a compound as defined above, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating autoimmune diseases in a subject.


[054] In further ~~aspect~~examples, the disclosure relates to use of a compound of Formula (I)-(VIII), or a a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of disease, such as cancer, and the use of such compounds and salts for treatment of such diseases.

[055] In further ~~aspect~~examples, the disclosure relates to a method of inhibiting a tyrosine kinase, such as EGFR, comprising contacting a cell comprising one or more of kinase with an effective amount of at least one compound of Formula (I)-(VIII), or a a pharmaceutically acceptable salt

thereof, and/or with at least one pharmaceutical composition of the disclosure, wherein the contacting is *in vitro, ex vivo,* or *in vivo*.

[056] Additional examples~~embodiments~~, features, and advantages of the disclosure will be apparent from the following detailed description and through practice of the disclosure. The compounds of the present disclosure can be described as ~~embodiments~~ examples in any of the following enumerated clauses. It will be understood that any of the ~~embodiments~~ examples described herein can be used in connection with any other ~~embodiments~~ examples described herein to the extent that the ~~embodiments~~examples do not contradict one another.

[057] 1. A compound of the formula I, or a pharmaceutically acceptable salt thereof,



I

[058] wherein

[059] A is a 5- to 10-membered heteroarylene or C_6-C_{10} arylene;

[060] each L is independently -C(R^3)(R^4)-, -C(O)-, -O-, -N(R^5)-, -S-, -S(O)- or -S(O)$_2$-, provided that $(L)_n$ does not comprise a –O-O-, a –O-S-, or a –O-N(R^5)- bond;

[061] X is N or C(R^6);

[062] X^1 is N or C(R^7);

[063] X^2 is N or C(R^8);

[064] X^3 is N or C(R^9);

[065] X^4 is N or C(R^{10});


[066] Y and Y^1 are each independently O or S;

[067] Y^2 is -O-, -N(R^{11})-, or -S-;

[068] Z is a 3- to 7-membered heterocycloalkylene, C_3-C_6 cycloalkylene, C_6-C_{10} arylene, 5- to 10-membered heteroarylene, -C(R^{12})(R^{13})-, -C(O)-, -O-, -N(R^{14})-, -S-, -S(O)- or -S(O)$_2$-, wherein each hydrogen atom in 3- to 7-membered heterocycloalkylene, C_3-C_6 cycloalkylene, C_6-C_{10} arylene, and 5- to 10-membered heteroarylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, -OR^e, -OC(O)R^e, -OC(O)N$R^e$$R^f$, -OS(O)$R^e$, -OS(O)$_2$$R^e$, -OS(O)N$R^e$$R^f$, -OS(O)$_2NR^e$$R^f$, -S$R^e$, -S(O)$R^e$, -S(O)$_2$$R^e$, -S(O)N$R^e$$R^f$,

WHAT IS CLAIMED IS:

1. A compound of the formula I, or a pharmaceutically acceptable salt thereof,



I

wherein

A is a 5- to 10-membered heteroarylene or C_6-C_{10} arylene;

each L is independently -C(R^3)(R^4)-, -C(O)-, -O-, -N(R^5)-, -S-, -S(O)- or -S(O)$_2$-, provided that $(L)_n$ does not comprise a –O-O-, a –O-S-, or a –O-N(R^5)- bond;

X is N or C(R^6);

X^1 is N or C(R^7);

X^2 is N or C(R^8);

X^3 is N or C(R^9);

X^4 is N or C(R^{10});

Y and Y^1 are each independently O or S;

Y^2 is -O-, -N(R^{11})-, or -S-;

Z is a 3- to 7-membered heterocycloalkylene, C_3-C_6 cycloalkylene, C_6-C_{10} arylene, 5- to 10-membered heteroarylene, -C(R^{12})(R^{13})-, -C(O)-, -O-, -N(R^{14})-, -S-, -S(O)- or -S(O)$_2$-, wherein each hydrogen atom in 3- to 7-membered heterocycloalkylene, C_3-C_6 cycloalkylene, C_6-C_{10} arylene, and 5- to 10-membered heteroarylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, -OR^e, -OC(O)R^e, -OC(O)N$R^e$$R^f$, -OS(O)$R^e$, -OS(O)$_2$$R^e$, -OS(O)N$R^e$$R^f$, -OS(O)$_2NR^e$$R^f$, -$SR^e$, -S(O)$R^e$, -S(O)$_2$$R^e$, -S(O)N$R^e$$R^f$, -S(O)$_2NR^e$$R^f$, -N$R^e$$R^f$, -N$R^e$C(O)$R^f$, -N$R^e$C(O)O$R^f$, -N$R^e$C(O)N$R^e$$R^f$, -N$R^e$S(O)$R^f$, -N$R^e$S(O)$_2$$R^f$, -N$R^e$S(O)N$R^e$$R^f$, -N$R^e$S(O)$_2NR^e$$R^f$, -C(O)$R^e$, -C(O)O$R^e$, -C(O)N$R^e$$R^f$, -P$R^e$$R^f$, -P(O)$R^e$$R^f$, -P(O)$_2$$R^e$$R^f$, -P(O)N$R^e$$R^f$, -P(O)$_2NR^e$$R^f$, -P(O)O$R^e$, -P(O)$_2OR^e$, -CN, or -NO$_2$;

Z^1 is –NR^2C(Y^1)-, –C(Y^1)NR^2-, -O-, -N(R^2)-, -S-, -S(O)- or -S(O)$_2$-,

each R^1 is independently deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered

heteroaryl, $-OR^a$, $-OC(O)R^a$, $-OC(O)NR^aR^b$, $-OS(O)R^a$, $-OS(O)_2R^a$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-OS(O)NR^aR^b$, $-OS(O)_2NR^aR^b$, $-NR^aR^b$, $-NR^aC(O)R^b$, $-NR^aC(O)OR^b$, $-NR^aC(O)NR^aR^b$, $-NR^aS(O)R^b$, $-NR^aS(O)_2R^b$, $-NR^aS(O)NR^aR^b$, $-NR^aS(O)_2NR^aR^b$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^aR^b$, $-PR^aR^b$, $-P(O)R^aR^b$, $-P(O)_2R^aR^b$, $-P(O)NR^aR^b$, $-P(O)_2NR^aR^b$, $-P(O)OR^a$, $-P(O)_2OR^a$, -CN, or $-NO_2$, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl, is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, -CN, or $-NO_2$;

each of R^2, $R^{5,}$ R^{11}, or R^{14} is independently H, deuterium, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^{e'}$, -CN, or $-NO_2$;

each R^3, R^4, R^{12} and R^{13} is independently H, deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, $-OR^c$, $-OC(O)R^c$, $-OC(O)NR^cR^d$, $-OC(=N)NR^cR^d$, $-OS(O)R^c$, $-OS(O)_2R^c$, $-OS(O)NR^cR^d$, $-OS(O)_2NR^cR^d$, $-SR^c$, $-S(O)R^c$, $-S(O)_2R^c$, $-S(O)NR^cR^d$, $-S(O)_2NR^cR^d$, $-NR^cR^d$, $-NR^cC(O)R^d$, $-N(C(O)R^c)(C(O)R^d)$, $-NR^cC(O)OR^d$, $-NR^cC(O)NR^cR^d$, $-NR^cC(=N)NR^cR^d$, $-NR^cS(O)R^d$, $-NR^cS(O)_2R^d$, $-NR^cS(O)NR^cR^d$, $-NR^cS(O)_2NR^cR^d$, $-C(O)R^c$, $-C(O)OR^c$, $-C(O)NR^cR^d$, $-C(=N)NR^cR^d$, $-PR^cR^d$, $-P(O)R^cR^d$, $-P(O)_2R^cR^d$, $-P(O)NR^cR^d$, $-P(O)_2NR^cR^d$, $-P(O)OR^c$, $-P(O)_2OR^c$, -CN, $-NO_2$, or two of R^3, R^4, R^{12}, and R^{13} taken together with the carbon or carbons to which they are attached form a C_3-C_6 cycloalkyl or a 4- to 6-membered heterocycloalkyl, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, or 4- to 6-membered heterocycloalkyl is independently optionally

substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OR^e, -$OC(O)R^e$, -$OC(O)NR^eR^f$, -$OS(O)R^e$, -$OS(O)_2R^e$, -$OS(O)NR^eR^f$, -$OS(O)_2NR^eR^f$, -SR^e, -$S(O)R^e$, -$S(O)_2R^e$, -$S(O)NR^eR^f$, -$S(O)_2NR^eR^f$, -NR^eR^f, -$NR^eC(O)R^f$, -$NR^eC(O)OR^f$, -$NR^eC(O)NR^eR^f$, -$NR^eS(O)R^f$, -$NR^eS(O)_2R^f$, -$NR^eS(O)NR^eR^f$, -$NR^eS(O)_2NR^eR^f$, -$C(O)R^e$, -$C(O)OR^e$, -$C(O)NR^eR^f$, -PR^eR^f, -$P(O)R^eR^f$, -$P(O)_2R^eR^f$, -$P(O)NR^eR^f$, -$P(O)_2NR^eR^f$, -$P(O)OR^e$, -$P(O)_2OR^e$, -CN, or -NO_2;

R^6 is H, deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, or –CN;

each of R^7 and R^8 is independently a bond to Z, H, deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, -OR^a, -$OC(O)R^a$, -$OC(O)NR^aR^b$, -$OS(O)R^a$, -$OS(O)_2R^a$, -SR^a, -$S(O)R^a$, -$S(O)_2R^a$, -$S(O)NR^aR^b$, -$S(O)_2NR^aR^b$, -$OS(O)NR^aR^b$, -$OS(O)_2NR^aR^b$, -NR^aR^b, -$NR^aC(O)R^b$, -$NR^aC(O)OR^b$, -$NR^aC(O)NR^aR^b$, -$NR^aS(O)R^b$, -$NR^aS(O)_2R^b$, -$NR^aS(O)NR^aR^b$, -$NR^aS(O)_2NR^aR^b$, -$C(O)R^a$, -$C(O)OR^a$, -$C(O)NR^aR^b$, -PR^aR^b, -$P(O)R^aR^b$, -$P(O)_2R^aR^b$, -$P(O)NR^aR^b$, -$P(O)_2NR^aR^b$, -$P(O)OR^a$, -$P(O)_2OR^a$, -CN, or -NO_2; wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl, is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OR^e, -$OC(O)R^e$, -$OC(O)NR^eR^f$, -$OS(O)R^e$, -$OS(O)_2R^e$, -$OS(O)NR^eR^f$, -$OS(O)_2NR^eR^f$, -SR^e, -$S(O)R^e$, -$S(O)_2R^e$, -$S(O)NR^eR^f$, -$S(O)_2NR^eR^f$, -NR^eR^f, -$NR^eC(O)R^f$, -$NR^eC(O)OR^f$, -$NR^eC(O)NR^eR^f$, -$NR^eS(O)R^f$, -$NR^eS(O)_2R^f$, -$NR^eS(O)NR^eR^f$, -$NR^eS(O)_2NR^eR^f$, -$C(O)R^e$, -$C(O)OR^e$, -$C(O)NR^eR^f$, -PR^eR^f, -$P(O)R^eR^f$, -$P(O)_2R^eR^f$, -$P(O)NR^eR^f$, -$P(O)_2NR^eR^f$, -$P(O)OR^e$, -$P(O)_2OR^e$, -CN, or -NO_2; provided that one of R^7 or R^8 is a bond to Z;

each of R^9 and R^{10} is independently H, deuterium, halogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, -OR^a, -$OC(O)R^a$, -$OC(O)NR^aR^b$, -$OS(O)R^a$, -$OS(O)_2R^a$, -SR^a, -$S(O)R^a$, -$S(O)_2R^a$, -$S(O)NR^aR^b$, -$S(O)_2NR^aR^b$, -$OS(O)NR^aR^b$, -$OS(O)_2NR^aR^b$, -NR^aR^b, -$NR^aC(O)R^b$, -$NR^aC(O)OR^b$, -$NR^aC(O)NR^aR^b$, -$NR^aS(O)R^b$, -$NR^aS(O)_2R^b$, -$NR^aS(O)NR^aR^b$, -$NR^aS(O)_2NR^aR^b$, -$C(O)R^a$, -$C(O)OR^a$, -$C(O)NR^aR^b$, -PR^aR^b, -$P(O)R^aR^b$, -$P(O)_2R^aR^b$, -$P(O)NR^aR^b$, -$P(O)_2NR^aR^b$, -$P(O)OR^a$, -$P(O)_2OR^a$, -CN, or -NO_2; or R^8 and R^9 or R^9 and R^{10} taken together with the carbons to which they are attached form a C_4-C_6 cycloalkyl, a 4- to 7-membered heterocycloalkyl, or a C_6-C_{10} aryl, wherein each hydrogen atom in C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_4-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, or 4- to 7-membered heterocycloalkyl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OR^e, -$OC(O)R^e$, -$OC(O)NR^eR^f$, -$OS(O)R^e$, -$OS(O)_2R^e$, -$OS(O)NR^eR^f$,


$-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, $-CN$, or $-NO_2$;

each R^a, R^b, R^c, R^d, R^e, and R^f is independently selected from the group consisting of H, deuterium, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C_6-C_{10} aryl, C_1-C_6 alkyl-C_6-C_{10} aryl, and 5- to 10-membered heteroaryl;

m is 0, 1, 2, 3, or 4; and

n is 2, 3, 4, 5, 6, 7, or 8.


2. The compound of claim 1 having the formula IV



IV

or a pharmaceutically acceptable salt thereof.

~~3. The compound of claim 1 having the formula VI~~


















~~VI~~

~~or a pharmaceutically acceptable salt thereof.~~

~~4~~3. The compound of ~~any one of~~ claim~~s~~ 1 ~~to~~or ~~3~~2, or a pharmaceutically acceptable salt thereof, wherein A is phenylene, furanylene, thiophenylene, pyrrolylene, oxazolylene, isoxazolylene, thiazolylene, isothiazolylene, pyrazolylene, imidazolylene, oxadiazolylene, thiadiazolylene, triazolylene, pyridinylene, pyrazinylene, pyrimidinylene, pyridazinylene, or triazinylene.

~~5. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein A is a pyrrolylene.~~

~~6~~4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein A is , , , , , , , , , , , or , wherein R^{1a} is C_1-C_6 alkyl, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^b, or -P(O)$_2$OR^a, wherein each hydrogen atom in C_1-C_6 alkyl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OR^e, -OC(O)R^e, -OC(O)NR^eR^f, -OS(O)R^e, -OS(O)$_2R^e$, -OS(O)NR^eR^f, -OS(O)$_2$NR^eR^f, -SR^e, -S(O)R^e, -S(O)$_2R^e$, -S(O)NR^eR^f, -S(O)$_2$NR^eR^f, -NR^eR^f, -NR^eC(O)R^f, -NR^eC(O)OR^f, -NR^eC(O)NR^eR^f, -NR^eS(O)R^f, -NR^eS(O)$_2R^f$, -NR^eS(O)NR^eR^f, -NR^eS(O)$_2$NR^eR^f, -C(O)R^e, -C(O)OR^e, -C(O)NR^eR^f, -PR^eR^f, -P(O)R^eR^f, -P(O)$_2R^eR^f$, -P(O)NR^eR^f, -P(O)$_2$NR^eR^f, -P(O)OR^e, -P(O)$_2$OR^e, -CN, or -NO$_2$.

~~7. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein A is~~  ~~,~~  ~~, or~~  ~~.~~

~~8. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, each R^1 is -CN or C_1-C_6 alkyl, wherein each hydrogen atom in C_1-C_6 alkyl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, -OR^e, -OC(O)R^e, -OC(O)NR^eR^f, -OS(O)R^e, -OS(O)$_2R^e$, -OS(O)NR^eR^f, -OS(O)$_2$NR^eR^f, -SR^e, -S(O)R^e, -S(O)$_2R^e$, -S(O)NR^eR^f, -S(O)$_2$NR^eR^f, -NR^eR^f, -NR^eC(O)R^f, -NR^eC(O)OR^f, -NR^eC(O)NR^eR^f, -NR^eS(O)R^f, -NR^eS(O)$_2R^f$, -NR^eS(O)NR^eR^f, -NR^eS(O)$_2$NR^eR^f, -C(O)R^e, -C(O)OR^e, -C(O)NR^eR^f, -PR^eR^f, -P(O)R^eR^f, -P(O)$_2R^eR^f$, -P(O)NR^eR^f, -P(O)$_2$NR^eR^f, -P(O)OR^e, -P(O)$_2$OR^e, -CN, or -NO$_2$.~~

~~9. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, each R^1 is -CN or methyl.~~
















~~10. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, R^{1a} is methyl.~~

~~11~~5. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^2 is H or C_1-C_6 alkyl, wherein each hydrogen atom in C_1-C_6 alkyl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^{e'}$, -CN, or $-NO_2$.

~~12. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^2 is H or methyl.~~






~~13. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Z is a 5- or 6-membered heteroarylene, wherein each hydrogen atom in 5- or 6-membered heteroarylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, -CN, or $-NO_2$.~~

~~14~~6. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Z is pyrazolylene, oxazolylene, thiazolylene, pyridinylene, pyrimidinylene, or pyridin-2-onylene, wherein each hydrogen atom in pyrazolylene, oxazolylene, thiazolylene, pyridinylene, pyrimidinylene, and pyridin-2-onylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, -CN, or $-NO_2$.

15. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Z is , , , , , , , , , , , , , , or .

16. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein Z is C_6-C_{10} arylene, wherein each hydrogen atom in C_6-C_{10} arylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, $-CN$, or $-NO_2$.

17. The compound of any one of claims 1 to 12 or 16, or a pharmaceutically acceptable salt thereof, wherein Z is phenylene, wherein each hydrogen atom in phenylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, $-CN$, or $-NO_2$.

18. The compound of any one of claims 1 to 12, 16, or 17, or a pharmaceutically acceptable salt thereof, wherein Z is , , , , .

19. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein Z is 3- to 7-membered heterocycloalkylene, wherein each hydrogen atom in 3- to 7-membered heterocycloalkylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, -CN, or $-NO_2$.

20. The compound of any one of claims 1 to 12 or 19, or a pharmaceutically acceptable salt thereof, wherein Z is pyrrolidonylene or azetidinylene, wherein each hydrogen atom in pyrrolidonylene and azetidinylene is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, -CN, or $-NO_2$.

21. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein Z is $-C(R^{12})(R^{13})-$, $-O-$, $-N(R^{14})-$, $-S-$, $-S(O)-$ or $-S(O)_2-$.

22. The compound of any one of claims 1 to 12 or 21, or a pharmaceutically acceptable salt thereof, wherein Z is $-C(R^{12})(R^{13})-$.

23. The compound of any one of the preceding claims, wherein R^{12} and R^{13} are independently selected from the group consisting of H, deuterium, fluoro, chloro, bromo, $-OR^e$, and C_1-C_6 alkyl; or R^{12} and R^{13} taken together with the carbon to which they are attached form a C_3-C_6 cycloalkyl or a 4- to 6-membered heterocycloalkyl, wherein each hydrogen atom in C_3-C_6 cycloalkyl or 4- to 6-membered heterocycloalkyl is independently optionally substituted by deuterium, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $-OR^e$, $-OC(O)R^e$, $-OC(O)NR^eR^f$, $-OS(O)R^e$, $-OS(O)_2R^e$, $-OS(O)NR^eR^f$, $-OS(O)_2NR^eR^f$, $-SR^e$, $-S(O)R^e$, $-S(O)_2R^e$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-NR^eR^f$, $-NR^eC(O)R^f$, $-NR^eC(O)OR^f$, $-NR^eC(O)NR^eR^f$, $-NR^eS(O)R^f$, $-NR^eS(O)_2R^f$, $-NR^eS(O)NR^eR^f$, $-NR^eS(O)_2NR^eR^f$, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-PR^eR^f$, $-P(O)R^eR^f$, $-P(O)_2R^eR^f$, $-P(O)NR^eR^f$, $-P(O)_2NR^eR^f$, $-P(O)OR^e$, $-P(O)_2OR^e$, -CN, or $-NO_2$.

~~24. The compound of any one of the preceding claims, wherein R^{12} is H and R^{13} is methyl.~~

~~25. The compound of any one of the preceding claims, wherein R^{12} is methyl and R^{13} is H.~~

~~26. The compound of any one of the preceding claims, wherein R^{12} and R^{13} are H.~~

~~27. The compound of any one of the preceding claims, wherein R^{12} is methyl and R^{13} is -OH.~~

~~28. The compound of any one of the preceding claims, wherein R^{12} is -OH and R^{13} is methyl.~~

~~29. The compound of any one of claims 1 to 12 or 21, or a pharmaceutically acceptable salt thereof, wherein Z is -O-.~~

~~30. The compound of any one of claims 1 to 12 or 21, or a pharmaceutically acceptable salt thereof, wherein Z is $-N(R^{14})-$.~~

~~31. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^{14} is H, deuterium, C_1-C_6 alkyl, or C_3-C_6 cycloalkyl.~~

~~32. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^{14} is H, methyl, or cyclopropyl.~~

~~33. The compound of any one of claims 1 to 12 or 21, or a pharmaceutically acceptable salt thereof, wherein Z is -S-.~~

~~34. The compound of any one of claims 1 to 12 or 21, or a pharmaceutically acceptable salt thereof, wherein Z is $-S(O)_2-$.~~

~~35~~7. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein n is ~~3~~5.

~~36. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein n is 4.~~

~~37. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein n is 5.~~

~~38. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein n is 6.~~

~~39. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein n is 7.~~

~~40~~8. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein each L is independently selected from the group consisting of -C(O)-, -O-, -CH_2-, -C(H)(CH_3)-, -C(H)(OH)-, -C(H)(C(O)OR^c)-, -C(H)(C(O)NR^cR^d)-, -NH-, and -NCH_3-.

~~41~~9. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein X is C(R^6).

~~42. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^6 is H.~~

~~43~~10. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Y is O.

~~44~~11. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Y^1 is O.

~~45~~12. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Y^2 is –N(R^{11})-.

~~46. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein X^1, when present, and X^3 are N.~~

~~47. The compound of any one of claims 1 to 45, or a pharmaceutically acceptable salt thereof, wherein X^1, when present, and X^4 are N.~~

~~48. The compound of any one of claims 1 to 45, or a pharmaceutically acceptable salt thereof, wherein X^3 and X^4 are N.~~

~~49. The compound of any one of claims 1 to 45, or a pharmaceutically acceptable salt thereof, wherein X^1, when present, is N.~~

~~50. The compound of any one of claims 1 to 45, or a pharmaceutically acceptable salt thereof, wherein X^2, when present, is N.~~

~~51. The compound of any one of claims 1 to 45, or a pharmaceutically acceptable salt thereof, wherein X^3 is N.~~

~~52. The compound of any one of claims 1 to 45, or a pharmaceutically acceptable salt thereof, wherein X^4 is N.~~

~~53~~13. The compound of any one of claims 1 to ~~45~~12, or a pharmaceutically acceptable salt thereof, wherein X^1 is $C(R^7)$, X^3 is $C(R^9)$, and X^4 is $C(R^{10})$.

~~54. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein $C(R^7)$, when present, is independently H, deuterium, fluoro, chloro, -CN, or methyl.~~

~~55. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein $C(R^8)$, when present, is independently H, deuterium, fluoro, chloro, -CN, or methyl.~~

~~56. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein $C(R^9)$, when present, is independently H, deuterium, fluoro, chloro, -CN, or methyl.~~

~~57. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein $C(R^{10})$, when present, is H.~~

~~58~~14. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein $–(L)_n-$ is $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-(CH_2)_5-$, $-(CH_2)_6-$,

-C(O)NH-$(CH_2)_2O(CH_2)_2$-, -C(O)N(CH_3)-$(CH_2)_2O(CH_2)_2$-, -NHC(O)$CH_2O(CH_2)_2$-, -N(CH_3)-C(O)$CH_2O(CH_2)_2$-, -$CH_2O(CH_2)_2$-, -$(CH_2)_2O(CH_2)_2$-, -$(CH_2)_2S(CH_2)_2$-, -$O(CH_2)_2S(CH_2)_2$-, -$(CH_2)_2SO_2(CH_2)_2$-, -$O(CH_2)_2SO_2(CH_2)_2$-, -$(CH_2)_2SO(CH_2)_2$-, -$O(CH_2)_2SO(CH_2)_2$-, -$(CH_2)_2O$(C(H)(C(O)N(H) (azetidin-3-yl))-CH_2-, -$(CH_2)_2O$(C(H)(C(O)N(H)(CH_3))-CH_2-, -$(CH_2)_2O$(C(H)(C(O)N$(CH_3)_2$)-CH_2-, -$(CH_2)_2O$(C(H)(C(O)N(H)(piperidin-4-yl))-CH_2-, -$(CH_2)_2O$(C(H)(C(O)N(H)(pyrrolidin-3-yl))-CH_2-, -$(CH_2)_2O$(C(H)(C(O)N(H)(4-methylpiperazin-1-yl))-CH_2-, -$(CH_2)_2O$(C(H)(C(O)OCH_3)-CH_2-, -$(CH_2)_3O(CH_2)_2$-, -$(CH_2)_2O(CH_2)_3$-, -$CH_2CH(CH_3)$-$O(CH_2)_2$-, -$CH(CH_3)$-$CH_2O(CH_2)_2$-, -$O(CH_2)_2$-, -O-$(CH_2)_3$-, -$OCH_2O(CH_2)_2$-, -O-$CH_2CH(OH)CH_2$-, -O-$(CH_2)_2O(CH_2)_2$-, -O-$CH_2CH(CH_3)$-$O(CH_2)_2$-, -O-$CH(CH_3)$-$CH_2O(CH_2)_2$-, -O-$(CH_2)_2NH$-$(CH_2)_2$-, -O-$CH_2CH(CH_3)$-NH-$(CH_2)_2$-, -O-$CH(CH_3)$-CH_2NH-$(CH_2)_2$-, -CH_2NH-$(CH_2)_2$-, -$(CH_2)_2NH$-$(CH_2)_2$-, -$CH_2CH(CH_3)$-NH-$(CH_2)_2$-, -$CH(CH_3)$-CH_2NH-$(CH_2)_2$-, -O-$(CH_2)_2N(CH_3)$-$(CH_2)_2$-, -O-$CH_2CH(CH_3)$-N(CH_3)-$(CH_2)_2$-, -O-$CH(CH_3)$-$CH_2N(CH_3)$-$(CH_2)_2$-, -$CH_2N(CH_3)$-$(CH_2)_2$-, -$CH_2N(CH_2CH_3)$-$(CH_2)_2$-, -$CH_2N(CH(CH_3))$-$(CH_2)_2$-, -$(CH_2)_2N(CH_3)$-$(CH_2)_2$-, -$CH_2CH(CH_3)$-N(CH_3)-$(CH_2)_2$-, or -O-$CH(CH_3)$-$CH_2N(CH_3)$-$(CH_2)_2$-.

~~59~~15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of [3a(4)*Z*]-10,11-dihydro-2*H*,13*H*-16,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]oxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-17,1-(azenometheno)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-1,17-(azenometheno)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-1,17-(diazanediylidene)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-17,1-(azenometheno)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-1,17-(azenometheno)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*,11*S*]-11-hydroxy-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[19a(20)*Z*]-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*,12*H*-15,17-(ethanediylidene)pyrazolo[4,3-*p*]dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7,14]dioxadiazacycloheptadecine-4,19(5*H*,18*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-3,8-dioxo-2,3,5,8,9,10,11,12-octahydro-14*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-6-carbonitrile;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)imidazo[4,5-*i*]pyrazolo[3,4-*b*]pyrrolo[3,4-*f*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,15-dimethyl-9,10,11,12-tetrahydro-15*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-1,17-(ethanediylidene)[1,2]oxazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,16-dimethyl-9,10,11,12-tetrahydro-1,17-(ethanediylidene)[1,2]oxazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-1,17-(ethanediylidene)dipyrrolo[3,4-*f*:2',3'-*i*][1,2]thiazolo[3,4-*b*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9-dimethyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9-dimethyl-9,10,11,12-tetrahydro-1,17-(ethanediylidene)[1,2]oxazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,16-trimethyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,16-trimethyl-9,10,11,12-tetrahydro-1,17-(ethanediylidene)[1,2]oxazolo[3,4-*b*]dipyrrolo[3,4-*f*:2',3'-*i*][1,5,12]oxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-1,17-(ethanediylidene)pyrazolo[5,1-*c*]dipyrrolo[3,2-*j*:3',4'-*m*][1,4,8]triazacyclotetradecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-17,1-(azenometheno)pyrazolo[1,5-*e*]dipyrrolo[3,4-*i*:2',3'-*l*][1,5]diazacyclotetradecine-3,8(2*H*,5*H*)-dione;
[19a(20)*Z*]-2-methyl-6,7,9,10-tetrahydro-1*H*-15,17-(ethanediylidene)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,19(5*H*,18*H*)-dione;
[19a(20)*Z*]-2-methyl-6,7,9,10-tetrahydro-1*H*-15,17-(azenometheno)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,14]oxadiazacyclohexadecine-4,19(5*H*,18*H*)-dione;

[19a(20)*Z*]-2-methyl-6,7,9,10-tetrahydro-1*H*-15,17-(azenometheno)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,19(5*H*,18*H*)-dione;
[19a(20)*Z*]-2-methyl-6,7,9,10-tetrahydro-1*H*-15,17-(ethanediylidene)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,14]oxadiazacyclohexadecine-4,19(5*H*,18*H*)-dione;
[10*R*,19a(20)*Z*]-2,10-dimethyl-6,7,9,10-tetrahydro-1*H*-15,17-(ethanediylidene)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,14]oxadiazacyclohexadecine-4,19(5*H*,18*H*)-dione;
[19a(20)*Z*]-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-15,17-(ethanediylidene)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,14]oxadiazacyclohexadecine-4,19(5*H*,18*H*)-dione;
[19a(20)*Z*]-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-15,17-(azenometheno)pyrazolo[1,5-*d*]dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,19(5*H*,18*H*)-dione;
[19a(20)*Z*]-2-methyl-5,6,7,8,9,10-hexahydro-15,17-(ethanediylidene)pyrazolo[1,5-*g*]dipyrrolo[3,4-*k*:2',3'-*n*][1,4,7]triazacyclohexadecine-4,19(1*H*,18*H*)-dione;
[19a(20)*Z*]-2,5-dimethyl-5,6,7,8,9,10-hexahydro-15,17-(ethanediylidene)pyrazolo[1,5-*g*]dipyrrolo[3,4-*k*:2',3'-*n*][1,4,7]triazacyclohexadecine-4,19(1*H*,18*H*)-dione;
[3a(4)*Z*]-6-methyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]oxadiazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6-methyl-10,11,13,14-tetrahydro-2*H*-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6-methyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6,9-dimethyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6,9,16-trimethyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9-dimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9-dimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-20-fluoro-6,9-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-19-fluoro-6,9-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,20-trimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,20-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,16-dimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,16-trimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-16-cyclopropyl-6,9-dimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-16-cyclopropyl-6,9-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,16-trimethyl-10,11,12,13-tetrahydro-2*H*-17,1-(azenometheno)[1,2]oxazolo[4,5-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6,9,16-trimethyl-10,11,12,13-tetrahydro-2*H*-17,1-(azenometheno)[1,2]oxazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6,14-dimethyl-10,11,13,14-tetrahydro-2*H*-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6,9,14-trimethyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6,9,14-trimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9,12,14-tetramethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9,16-trimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9,16-trimethyl-10,11-dihydro-2*H*,13*H*-1,17-(ethanediylidene)[1,2]oxazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-6,9,16-trimethyl-10,11,12,13-tetrahydro-2*H*-1,17-(ethanediylidene)[1,2]oxazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-6,9,12,14,16-pentamethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9,14,16-tetramethyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9,14,16-tetramethyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-9,14,16-trimethyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-9,14,16-trimethyl-10,11,13,14-tetrahydro-2*H*-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-12-ethyl-6,9,14-trimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9,14-trimethyl-12-(propan-2-yl)-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-16-cyclopropyl-6,9-dimethyl-10,11-dihydro-2*H*,13*H*-1,17-(ethanediylidene)[1,2]oxazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-9,14-dimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;

[3a(4)*Z*]-6,9-dimethyl-16-(propan-2-yl)-10,11-dihydro-2*H*,13*H*-1,17-(ethanediylidene)[1,2]oxazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-9-methyl-16-(propan-2-yl)-10,11-dihydro-2*H*,13*H*-1,17-(ethanediylidene)[1,2]oxazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]oxazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6,9,14-trimethyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,14-dimethyl-9,10,11,12-tetrahydro-14*H*-1,17-(ethanediylidene)pyrazolo[4,3-*n*]dipyrrolo[3,2-*g*:3',4'-*j*][1,5]oxazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,12,14-tetramethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-9,12,14-trimethyl-9,10,11,12,13,14-hexahydro-17,1-(azenometheno)pyrazolo[4,3-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4]diazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6,9,12,14-tetramethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione; and
[3a(4)*Z*]-9,12,14-trimethyl-9,10,11,12,13,14-hexahydro-1,17-(ethanediylidene)pyrazolo[3,4-*f*]dipyrrolo[3,4-*j*:2',3'-*m*][1,4,9]triazacyclopentadecine-3,8(2*H*,5*H*)-dione.

~~60~~16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of [3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-1,18-(ethanediylidene)dipyrrolo[3,2-*g*:3',4'-*j*][1,5,12]benzoxadiazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[3a(4)*Z*]-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]benzoxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6-methyl-10,11-dihydro-2*H*-17,1-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4]benzoxazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-16-fluoro-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]benzoxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-15-fluoro-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]benzoxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-14-fluoro-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]benzoxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;

[3a(4)*Z*]-13-fluoro-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]benzoxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione; and
[3a(4)*Z*]-6,9,12-trimethyl-10,11,12,13-tetrahydro-2*H*-1,18-(ethanediylidene)dipyrrolo[3,2-*g*:3',4'-*j*][2,5]benzodiazacyclopentadecine-3,8(5*H*,9*H*)-dione.

~~61~~17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of [3a(4)*Z*]-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)pyrido[3,2-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]oxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6-methyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)pyrimido[5,4-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]oxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6,16-dimethyl-10,11-dihydro-2*H*-1,17-(ethanediylidene)pyrido[3,4-*m*]dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11]oxadiazacyclotetradecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-14*H*-1,18-(ethanediylidene)pyrido[2,1-*c*]dipyrrolo[3,2-*j*:3',4'-*m*][1,4,8]triazacyclotetradecine-3,8,14(2*H*,5*H*)-trione;
[3a(4)*Z*]-6-methyl-9,10,11,12-tetrahydro-14*H*-18,1-(azenometheno)pyrido[1,2-*e*]dipyrrolo[3,4-*i*:2',3'-*l*][1,5]diazacyclotetradecine-3,8,14(2*H*,5*H*)-trione;
or a pharmaceutically acceptable salt thereof.

~~62~~18. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of [3a(4)*Z*,13a*R*]-6-methyl-10,11,12,13,13a,14,15,16-octahydro-2*H*-18,1-(azenometheno)tripyrrolo[1,2-*a*:3',2'-*i*:3'',4''-*l*][1,4,7]triazacyclopentadecine-3,8(5*H*,9*H*)-dione;
[3a(4)*Z*,13a*R*]-6-methyl-9,10,11,12,13,13a,14,15-octahydro-17,1-(azenometheno)azeto[1,2-*a*]dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]triazacyclopentadecine-3,8(2*H*,5*H*)-dione;
[16a(17)*Z*]-2,11-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-12,14-(azenometheno)dipyrrolo[3,4-*g*:2',3'-*j*][1,4,6,13]oxatriazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-2,5,11-trimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-12,14-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,13]oxadiazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[17a(18)*Z*]-2,12-dimethyl-6,7,9,10,11,12-hexahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,13]oxadiazacyclohexadecine-4,17(5*H*,16*H*)-dione;
[17a(18)*Z*]-2,5,12-trimethyl-6,7,9,10,11,12-hexahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,13]oxadiazacyclohexadecine-4,17(5*H*,16*H*)-dione;

[17a(18)*Z*]-2,5,12-trimethyl-6,7,9,10,11,12-hexahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,11,13]oxatriazacyclohexadecine-4,17(5*H*,16*H*)-dione;

[16a(17)*Z*]-2,5,11-trimethyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]triazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-2,5,11-trimethyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*k*:3',4'-*n*][1,3,6,9]tetraazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-2,5,11-trimethyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,2-*k*:3',4'-*n*][1,3,6,9]tetraazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-11-cyclopropyl-2,5-dimethyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*k*:3',4'-*n*][1,3,6,9]tetraazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-11-cyclopropyl-2-methyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,2-*k*:3',4'-*n*][1,3,6,9]tetraazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*R*,16a(17)*Z*]-2,5,10-trimethyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]triazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,8,9,10,11-hexahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]triazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-12,14-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,13]oxadiazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-12,14-(azenometheno)dipyrrolo[3,4-*g*:2',3'-*j*][1,4,6,13]oxatriazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,4-*d*:2',3'-*g*][1,13,3,10]dioxadiazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,4-*d*:2',3'-*g*][1,13,3,10]dioxadiazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-5,6,7,8,9,10-hexahydro-12,14-(azenometheno)dipyrrolo[3,4-*d*:2',3'-*g*][1,3,10,13]oxatriazacyclopentadecine-4,16(1*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-5,6,7,8,9,10-hexahydro-12,14-(ethanediylidene)dipyrrolo[3,4-*d*:2',3'-*g*][1,3,10,13]oxatriazacyclopentadecine-4,16(1*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-5,6,7,8,9,10-hexahydro-12,14-(azenometheno)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxadiazacyclopentadecine-4,16(1*H*,15*H*)-dione;

[9*R*,16a(17)*Z*]-2,5,9-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,4-*d*:2',3'-*g*][1,13,3,10]dioxadiazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[9*S*,16a(17)*Z*]-2,5,9-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(azenometheno)dipyrrolo[3,4-*d*:2',3'-*g*][1,13,3,10]dioxadiazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*R*,16a(17)*Z*]-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,10-dimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-5,6,7,8,9,10-hexahydro-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxadiazacyclopentadecine-4,16(1*H*,15*H*)-dione;

[9*R*,16a(17)*Z*]-2,5,9-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[9*S*,16a(17)*Z*]-2,5,9-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[17a(18)*Z*]-2-methyl-6,7,10,11-tetrahydro-1*H*,9*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,13,4]oxathiazacyclohexadecine-4,17(5*H*,16*H*)-dione;

[17a(18)*Z*]-2-methyl-6,7,10,11-tetrahydro-1*H*-13,15-(ethanediylidene)-12λ^6-dipyrrolo[3,2-*f*:3',4'-*i*][1,13,4]oxathiazacyclohexadecine-4,12,12,17(5*H*,9*H*,16*H*)-tetrone;

[17a(18)*Z*]-2-methyl-6,7,9,10-tetrahydro-1*H*,12*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclohexadecine-4,17(5*H*,16*H*)-dione;

[12*R*,17a(18)*Z*]-2,12-dimethyl-6,7,9,10-tetrahydro-1*H*,12*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclohexadecine-4,17(5*H*,16*H*)-dione;

[12*S*,17a(18)*Z*]-2,12-dimethyl-6,7,9,10-tetrahydro-1*H*,12*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclohexadecine-4,17(5*H*,16*H*)-dione;
[12*S*,17a(18)*Z*]-2,5,12-trimethyl-6,7,9,10-tetrahydro-1*H*,12*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclohexadecine-4,17(5*H*,16*H*)-dione;
[17a(18)*Z*]-2,5-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,14]oxadiazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;
[17a(18)*Z*]-2,5-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;
[17a(18)*Z*]-2,5-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,14]oxadiazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;
[17a(18)*Z*]-2,5-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(ethanediylidene)dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;
[12*S*,17a(18)*Z*]-2,5,12-trimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(ethanediylidene)dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;
[17a(18)*Z*]-2-methyl-6,7,11,12-tetrahydro-1*H*-13,15-(ethanediylidene)dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;
[17a(18)*Z*]-2,11-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(ethanediylidene)dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;
[17a(18)*Z*]-2,11-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,14]oxadiazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;
[17a(18)*Z*]-2,11-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,4-*h*:2',3'-*k*][1,4,7,14]oxatriazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;
[17a(18)*Z*]-2,11-dimethyl-6,7,11,12-tetrahydro-1*H*-13,15-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,14]oxadiazacyclohexadecine-4,10,17(5*H*,9*H*,16*H*)-trione;
[18a(19)*Z*]-2-methyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[18a(19)*Z*]-2,5-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[18a(19)*Z*]-2,11-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[13*S*,18a(19)*Z*]-2,13-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;

[13*R*,18a(19)*Z*]-2,13-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[18a(19)*Z*]-2-methyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(azenometheno)dipyrrolo[3,4-*i*:2',3'-*l*][1,4,8,15]oxatriazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[13*S*,18a(19)*Z*]-2,13-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,4-*i*:2',3'-*l*][1,4,8,15]oxatriazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[13*S*,18a(19)*Z*]-2,13-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(azenometheno)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[13*S*,18a(19)*Z*]-13-hydroxy-2,13-dimethyl-6,7,10,11-tetrahydro-1*H*,9*H*-14,16-(ethanediylidene)dipyrrolo[3,2-*f*:3',4'-*i*][1,4,15]oxadiazacycloheptadecine-4,12,18(5*H*,13*H*,17*H*)-trione;
[16a(17)*Z*]-2-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-19-chloro-2-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
[16a(17)*Z*]-19-chloro-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;
methyl [7*R*,16a(17)*Z*]-19-chloro-2,5-dimethyl-4,16-dioxo-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-7-carboxylate;
[7*R*,16a(17)*Z*]-*N*-(azetidin-3-yl)-19-chloro-2,5-dimethyl-4,16-dioxo-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-7-carboxamide;
[7*R*,16a(17)*Z*]-19-chloro-2,5-dimethyl-4,16-dioxo-*N*-(piperidin-4-yl)-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-7-carboxamide;
[7*R*,16a(17)*Z*]-19-chloro-*N*,2,5-trimethyl-4,16-dioxo-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-7-carboxamide;
[7*R*,16a(17)*Z*]-19-chloro-2,5-dimethyl-4,16-dioxo-*N*-[(3*R*)-pyrrolidin-3-yl]-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-7-carboxamide;

[7*R*,16a(17)*Z*]-19-chloro-*N*,*N*,2,5-tetramethyl-4,16-dioxo-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-7-carboxamide;

[7*R*,16a(17)*Z*]-19-chloro-2,5-dimethyl-7-(4-methylpiperazine-1-carbonyl)-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[10*S*,16a(17)*Z*]-19-chloro-2,5,10-trimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-19-chloro-5-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-19-chloro-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxathiazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-19-chloro-2,5-dimethyl-5,6,7,8,9,10-hexahydro-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxadiazacyclopentadecine-4,16(1*H*,15*H*)-dione;

[16a(17)*Z*]-19-chloro-2,5-dimethyl-6,7,9,10-tetrahydro-12,14-(ethanediylidene)-8λ^6-dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxathiazacyclopentadecine-4,8,8,16(1*H*,5*H*,15*H*)-tetrone;

[16a(17)*Z*]-19-chloro-2,5-dimethyl-6,7,9,10-tetrahydro-12,14-(ethanediylidene)-8λ^4-dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxathiazacyclopentadecine-4,8,16(1*H*,5*H*,15*H*)-trione;

[16a(17)*Z*]-19-chloro-5-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxathiazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,4-*g*:2',3'-*j*][1,4,13]oxathiazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-2,5-dimethyl-6,7-dihydro-1*H*,9*H*-12,14-(ethanediylidene)-11λ^6-dipyrrolo[3,4-*g*:2',3'-*j*][1,4,13]oxathiazacyclopentadecine-4,11,11,16(5*H*,10*H*,15*H*)-tetrone;

[16a(17)*Z*]-5-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,4-*g*:2',3'-*j*][1,4,13]oxathiazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-19-chloro-5-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)pyrazolo[4,3-*i*]pyrrolo[3,4-*l*][1,4,7]dioxazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-19-chloro-5-methyl-5,6,7,8,9,10-hexahydro-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxadiazacyclopentadecine-4,16(1*H*,15*H*)-dione;

[16a(17)*Z*]-19-chloro-2,5,8-trimethyl-5,6,7,8,9,10-hexahydro-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]oxadiazacyclopentadecine-4,16(1*H*,15*H*)-dione;

[16a(17)*Z*]-2,5-dimethyl-4,16-dioxo-4,5,6,7,9,10,15,16-octahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,2-*i*:3',4'-*l*][1,4,7]dioxazacyclopentadecine-19-carbonitrile;

[16a(17)*Z*]-19-chloro-2,5-dimethyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,4-*g*:2',3'-*j*][1,4,13]oxathiazacyclopentadecine-4,16(5*H*,15*H*)-dione;

[16a(17)*Z*]-19-chloro-5-methyl-6,7,9,10-tetrahydro-1*H*-12,14-(ethanediylidene)dipyrrolo[3,4-*g*:2',3'-*j*][1,4,13]oxathiazacyclopentadecine-4,16(5*H*,15*H*)-dione;and

[16a(17)*Z*]-19-chloro-5-methyl-6,7-dihydro-1*H*,9*H*-12,14-(ethanediylidene)-11λ^6-dipyrrolo[3,4-*g*:2',3'-*j*][1,4,13]oxathiazacyclopentadecine-4,11,11,16(5*H*,10*H*,15*H*)-tetrone.

~~63~~19. A pharmaceutical composition comprising at least one compound of any one of claims 1 to ~~62~~18, or a pharmaceutical acceptable salt thereof, and optionally one or more pharmaceutically acceptable excipients.

~~64. A method of treating disease, such as cancer, comprising administering to a subject in need of such treatment an effective amount of a compound of any one of claims 1 to 62, or a pharmaceutically acceptable salt thereof.~~

~~65. A compound of any one of claims 1 to 62, or a pharmaceutically acceptable salt thereof, for use in a method of treating cancer in a subject.~~

~~66. A compound of any one of claims 1 to 62, or a pharmaceutically acceptable salt thereof, for treating cancer in a subject.~~

~~67~~20. Use of a compound of any one of claims 1 to ~~62~~19, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating ~~cancer~~ autoimmune diseases in a subject.